AICAR vs Metformin
limited vs FDA Approved
monitor Researched · 90% Both activate AMPK through different mechanisms. Combined use may have additive effects on glucose metabolism.
Molecular Data
AICAR Metformin
Weight 338.21 Da 129.16 Da
Half-life ~2-3 hours ~5 hours
Type Nucleoside analog Biguanide (C4H11N5)
Key Benefits
AICAR
01 AMPK pathway activation
02 Enhanced fatty acid oxidation
03 Improved glucose uptake
04 Potential endurance enhancement
05 Mitochondrial biogenesis stimulation
Metformin
01 Improved insulin sensitivity and glucose regulation
02 Activation of AMPK, the master metabolic energy sensor
03 Potential lifespan extension and delay of age-related diseases (under investigation in TAME trial)
04 Reduced hepatic glucose output (gluconeogenesis suppression)
05 Modest weight loss or weight neutrality compared to other diabetes medications
06 Anti-inflammatory effects through NF-kB pathway suppression
07 Potential anti-cancer properties via mTOR inhibition and AMPK activation
08 Improved lipid profile with modest reductions in LDL cholesterol and triglycerides
Dosing Protocols
AICAR
1-5mg daily / Once daily
Standard Protocol 1-3mg Daily
Gradual Introduction 1mg → 2mg → 3mg Daily, titrating over 4 weeks
Advanced Protocol 3-5mg Daily for 8-12 weeks
Metformin
500-2000 mg/day / 1-2x daily with meals
Side Effects
AICAR
Injection site reactions
Mild fatigue during adaptation
Potential hypoglycemia
Metformin
Gastrointestinal distress (nausea, diarrhea, bloating, abdominal cramping) - most frequent complaint, affects up to 25% of users
Metallic taste in mouth
Decreased appetite
Flatulence and abdominal distension
Loose stools, particularly when initiating therapy or increasing dose
Contraindications
Diabetes (risk of hypoglycemia)
Cardiac conditions
Pregnancy or breastfeeding
Competitive athletes (WADA prohibited)
Severe renal impairment (eGFR below 30 mL/min/1.73m2)
Acute or chronic metabolic acidosis, including diabetic ketoacidosis
Known hypersensitivity to metformin
Acute conditions with potential for tissue hypoxia (decompensated heart failure, respiratory failure, recent MI, sepsis)
Severe hepatic impairment
Excessive alcohol intake (increases risk of lactic acidosis)
Research Evidence
AICAR Metformin
Status limited FDA Approved
References 2 studies 5 studies
Latest — 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.